A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• P. Bedano, M. Edelman, S. Nattam, D. Waterhouse, J. Shen, M. Yu, J. Harvey, J. Vinson, A. White, B. Bottema, N. Hanna. A Phase I-IIa Dose Ranging Study of Pemetrexed plus Cetuximab in Patients (pts) with Recurrent Non-Small Cell Lung Cancer (NSCLC): Analysis of the Completed Phase I Portion of HOG-LUN04-79. Poster presentation at the 4th IASLC International Chicago Symposium on Malignancies of the Chest and Head and Neck, October 26-28, 2006.

Manuscripts/Articles:

• Jalal S, Waterhouse D, Edelman MJ, Nattam S, Ansari R, Koneru K, Clark R, Richards A, Wu J, Yu M, Bottema B, White A, Hanna N. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group. J Thorac Oncol. 2009 Nov;4(11):1420-4. doi: 10.1097/JTO.0b013e3181b624ae. See abstract.